Literature DB >> 24572998

Treatment of Kawasaki disease with anti-TNF antibodies.

Michael Levin1, David Burgner2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24572998     DOI: 10.1016/S0140-6736(14)60131-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease.

Authors:  Seyyedeh Saneeymehri; Katherine Baker; Tsz-Yin So
Journal:  J Pediatr Pharmacol Ther       Date:  2015 May-Jun

2.  Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis.

Authors:  Yayoi Kimura; Masakatsu Yanagimachi; Yoko Ino; Mao Aketagawa; Michie Matsuo; Akiko Okayama; Hiroyuki Shimizu; Kunihiro Oba; Ichiro Morioka; Tomoyuki Imagawa; Tetsuji Kaneko; Shumpei Yokota; Hisashi Hirano; Masaaki Mori
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

3.  Clinical Proteomics Profiling for Biomarker Identification Among Patients Suffering With Indian Post Kala Azar Dermal Leishmaniasis.

Authors:  Priyank Jaiswal; Manab Ghosh; Goutam Patra; Bibhuti Saha; Sumi Mukhopadhyay
Journal:  Front Cell Infect Microbiol       Date:  2020-05-27       Impact factor: 5.293

4.  Clinical characteristics of Kawasaki disease complicated with Mycoplasma pneumoniae pneumonia: A retrospective study.

Authors:  Yinle Lan; Shuxian Li; Dehua Yang; Junfen Zhou; Yingshuo Wang; Jianhua Wang; Yingchun Xu; Zhimin Chen
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

5.  Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease.

Authors:  Chun-Na Zhao; Zhong-Dong Du; Ling-Ling Gao
Journal:  Chin Med J (Engl)       Date:  2016-04-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.